Yingsheng Biology
Founded Year
2009Stage
Series C | AliveAbout Yingsheng Biology
Yingsheng Biology focuses on the application of molecular diagnostic techniques in maternal health, neonatal genetic diseases, metabolic diseases and birth defects related to human genetic gene, national eugenic engineering fields.
Missing: Yingsheng Biology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Yingsheng Biology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Yingsheng Biology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Yingsheng Biology is included in 2 Expert Collections, including Omics.
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Women's Health & Wellness
1,493 items
Startups focused on providing products and services catering to women's health and wellbeing.
Latest Yingsheng Biology News
Apr 8, 2021
Didi’s autonomous driving unit releases 5 hours of continuous road test video Today, Didi Chuxing, China’s largest ride hailing firm, released a video of autonomous driving test without human driver takeover for 5 consecutive hours. Meng Xing, COO of Didi’s autonomous driving unit, connected with Sebastian Thrun, founder and chairman of Udacity and head of Google’s driverless project. The video was shot in the afternoon and went through day, dusk and night. The tested vehicle drove in Jiading District, Shanghai, passing by business district, factory, office and residential districts with dense traffic. SAIC Motor is trying to minimize the impact of chip shortages by strengthening global supply chain coordination Regarding the issue of chip supply, SAIC Motor responded that the issue of chips is a common problem faced by the global automotive industry. The main reason for the shortage of automotive chips is the imbalance between supply and demand. The company is minimizing the impact by strengthening global supply chain coordination and other measures. Although the shortage of chips will continue for a period of time, SAIC has a strong industrial chain system advantage and will overcome difficulties together with the industry. Abogen Biosciences completes a RMB600 million series B round financing Chinese biotechnology company Abogen Biosciences has recently raised RMB600 million (US$91.6 million) in a series B round financing. The round was co-led by PICC Capital, SDIC Venture Capital and Yunfeng Capital. Healthcare focused venture capital firms such as LYFE Capital and HighLight Capital, as well as existing investors such as Hillhouse Capital, TF Capital, Ming Bioventures also participated in the round of financing. The proceeds raised will be mainly used to accelerate the research and development of COVID-19 vaccine, build a vaccine industry base and further expand the product pipeline. Alibaba Health co-lead new round in Yingsheng Biology Today, Alibaba Health completed a joint investment in Yingsheng Biology, a Chinese clinical mass spectrometry company. Zijin Hongyun Fund, jointly managed by Huatai Zijin Investment and Alibaba Health (Co-GP), led the round. The proceeds of the latest round will be used to support R&D investment, market layout, and expansion of production capacity. Mass spectrometry technology is a cutting-edge innovative technology in the medical field. It has the characteristics of high sensitivity, high specificity, high accuracy, wide linear range and high throughput. It is used in clinical biochemical testing, immunological testing, microbiological testing, and clinical molecular biology and other clinical fields with deep application potential and technological value. Beyond Meat’s China plant completed Beyond Meat Inc. announced that its new China plant located in the Jiaxing Economic and Technological Development Zone near Shanghai has been officially completed and opened. In addition, Beyond Meat plans to enter new sales channels such as e-commerce in the future. The new factory will mainly produce plant-based pork, beef and poultry products, including the first innovative product specifically designed for the Chinese market-Beyond Pork. Beyond Meat has previously stated that China’s new plant is expected to be fully operational in early 2021. (China Money Network’s articles are curated and translated from credible Chinese media organizations with established brands, experienced editorial teams, and trustworthy journalism practices. However, we are not responsible for the accuracy of the information. For any questions, please reach out to our editorial department.)
Yingsheng Biology Frequently Asked Questions (FAQ)
When was Yingsheng Biology founded?
Yingsheng Biology was founded in 2009.
Where is Yingsheng Biology's headquarters?
Yingsheng Biology's headquarters is located at Building 12, No. 1777, Dazheng Road, High-tech Zone, Jinan.
What is Yingsheng Biology's latest funding round?
Yingsheng Biology's latest funding round is Series C.
Who are the investors of Yingsheng Biology?
Investors of Yingsheng Biology include bioVENTURE, Sunz Fund, Hillhouse Capital Management, CDBI Partners, China Capital Investment Group and 13 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.